A Cell-Based Approach to the Treatment of Inflammatory Bowel Disease - Entering an Era of Regenerative Medicine

Amy Lightner

Research output: Contribution to journalArticle

Abstract

Corticosteroids, and more recently biologics, have been the mainstay of therapy for patients with inflammatory bowel disease. Unfortunately, both are fraught with side effects and limited by lack of efficacy or loss of response. Many patients ultimately succumb to medically refractory disease and require an operation. As we enter an era of regenerative medicine, a new genre of cell-based therapeutics offers significant promise for both an improved safety profile and improved efficacy compared with conventional treatment approaches. The ability to restore and rebuild health with autologous products rather than react to disease with pharmaceuticals gives hope to those who treat inflammatory bowel disease. The rationale and ongoing trials in an emerging field of medicine - regenerative medicine - is herein discussed.

Original languageEnglish (US)
Pages (from-to)1689-1694
Number of pages6
JournalInflammatory Bowel Diseases
Volume24
Issue number9
DOIs
StatePublished - Aug 16 2018

Fingerprint

Regenerative Medicine
Inflammatory Bowel Diseases
Biological Products
Adrenal Cortex Hormones
Therapeutics
Medicine
Safety
Health
Pharmaceutical Preparations

Keywords

  • clinical trial
  • stem cell biology
  • surgery

ASJC Scopus subject areas

  • Immunology and Allergy
  • Gastroenterology

Cite this

A Cell-Based Approach to the Treatment of Inflammatory Bowel Disease - Entering an Era of Regenerative Medicine. / Lightner, Amy.

In: Inflammatory Bowel Diseases, Vol. 24, No. 9, 16.08.2018, p. 1689-1694.

Research output: Contribution to journalArticle

@article{5ffcf172084d4207989e6ef99b5b9294,
title = "A Cell-Based Approach to the Treatment of Inflammatory Bowel Disease - Entering an Era of Regenerative Medicine",
abstract = "Corticosteroids, and more recently biologics, have been the mainstay of therapy for patients with inflammatory bowel disease. Unfortunately, both are fraught with side effects and limited by lack of efficacy or loss of response. Many patients ultimately succumb to medically refractory disease and require an operation. As we enter an era of regenerative medicine, a new genre of cell-based therapeutics offers significant promise for both an improved safety profile and improved efficacy compared with conventional treatment approaches. The ability to restore and rebuild health with autologous products rather than react to disease with pharmaceuticals gives hope to those who treat inflammatory bowel disease. The rationale and ongoing trials in an emerging field of medicine - regenerative medicine - is herein discussed.",
keywords = "clinical trial, stem cell biology, surgery",
author = "Amy Lightner",
year = "2018",
month = "8",
day = "16",
doi = "10.1093/ibd/izy084",
language = "English (US)",
volume = "24",
pages = "1689--1694",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - A Cell-Based Approach to the Treatment of Inflammatory Bowel Disease - Entering an Era of Regenerative Medicine

AU - Lightner, Amy

PY - 2018/8/16

Y1 - 2018/8/16

N2 - Corticosteroids, and more recently biologics, have been the mainstay of therapy for patients with inflammatory bowel disease. Unfortunately, both are fraught with side effects and limited by lack of efficacy or loss of response. Many patients ultimately succumb to medically refractory disease and require an operation. As we enter an era of regenerative medicine, a new genre of cell-based therapeutics offers significant promise for both an improved safety profile and improved efficacy compared with conventional treatment approaches. The ability to restore and rebuild health with autologous products rather than react to disease with pharmaceuticals gives hope to those who treat inflammatory bowel disease. The rationale and ongoing trials in an emerging field of medicine - regenerative medicine - is herein discussed.

AB - Corticosteroids, and more recently biologics, have been the mainstay of therapy for patients with inflammatory bowel disease. Unfortunately, both are fraught with side effects and limited by lack of efficacy or loss of response. Many patients ultimately succumb to medically refractory disease and require an operation. As we enter an era of regenerative medicine, a new genre of cell-based therapeutics offers significant promise for both an improved safety profile and improved efficacy compared with conventional treatment approaches. The ability to restore and rebuild health with autologous products rather than react to disease with pharmaceuticals gives hope to those who treat inflammatory bowel disease. The rationale and ongoing trials in an emerging field of medicine - regenerative medicine - is herein discussed.

KW - clinical trial

KW - stem cell biology

KW - surgery

UR - http://www.scopus.com/inward/record.url?scp=85054911628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054911628&partnerID=8YFLogxK

U2 - 10.1093/ibd/izy084

DO - 10.1093/ibd/izy084

M3 - Article

C2 - 29788100

AN - SCOPUS:85054911628

VL - 24

SP - 1689

EP - 1694

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 9

ER -